The market is segmented based on , By Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), Drug (First-Generation, Second-Generation, Third-Generation), Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers) - Industry Trends and Forecast to 2030.
.
The Global Epilepsy Market size was valued at USD 2280.00 USD Million in 2022.
The Global Epilepsy Market is projected to grow at a CAGR of 6.9% during the forecast period of 2023 to 2030.
The major players operating in the market include Pfizer Inc. , Novartis AG , Abbott , Neurelis Inc. , GSK plc , Johnson &, Johnson Services Inc. , Teva Pharmaceutical Industries Ltd. , Sumitomo Dainippon Pharma Co. Ltd , Bausch Health Companies Inc. , Sanofi , Takeda Pharmaceutical Company Limited , UCB S.A. , Marinus Pharmaceuticals Inc. , Eisai Co. Ltd , H. Lundbeck A/S , Supernus Pharmaceuticals Inc , and DAIICHI SANKYO COMPANY LIMITED .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.